KALV Key Statistics, Chart & Performance
The current stock price of KALV is 15.17 USD. In the past month the price increased by 7.59%. In the past year, price increased by 77.84%.
KALV Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.34 | 406.46B | ||
| AMGN | AMGEN INC | 15.22 | 179.28B | ||
| GILD | GILEAD SCIENCES INC | 15.23 | 154.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.66 | 117.45B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.44 | 82.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.47 | 52.92B | ||
| INSM | INSMED INC | N/A | 37.94B | ||
| NTRA | NATERA INC | N/A | 32.26B | ||
| BIIB | BIOGEN INC | 10.58 | 25.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.22 | 21.84B | ||
| INCY | INCYTE CORP | 15.59 | 19.65B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About KALV
Company Profile
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. The company is headquartered in Framingham, Massachusetts and currently employs 270 full-time employees. The company went IPO on 2015-04-09. The firm is focused on the discovery, development and commercialization of drug therapies for diseases with significant unmet need. Its product candidate is sebetralstat, an inhibitor of plasma kallikrein being developed for hereditary angioedema (HAE). Sebetralstat is designed to offer people living with HAE a medication that can be taken as a discreet oral dose to readily treat HAE attacks on-demand, including at the earliest signs before the attack fully develops. Sebetralstat works by targeting the kallikrein-kinin system (KKS) cascade, selectively inhibiting plasma kallikrein and its uncontrolled activity that drives HAE attacks. The firm is also designing an oral Factor XIIa inhibitor for HAE prophylaxis, positioning KalVista to address the full spectrum of HAE disease management. Factor XIIa inhibitor program is developed to address other therapeutic areas, including inflammation and thrombosis.
Company Info
KALVISTA PHARMACEUTICALS INC
200 Crossing Boulevard
Framingham MASSACHUSETTS 02142 US
CEO: T. Andrew Crockett
Employees: 270
Phone: 18579990075
KALVISTA PHARMACEUTICALS INC / KALV FAQ
Can you describe the business of KALVISTA PHARMACEUTICALS INC?
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. The company is headquartered in Framingham, Massachusetts and currently employs 270 full-time employees. The company went IPO on 2015-04-09. The firm is focused on the discovery, development and commercialization of drug therapies for diseases with significant unmet need. Its product candidate is sebetralstat, an inhibitor of plasma kallikrein being developed for hereditary angioedema (HAE). Sebetralstat is designed to offer people living with HAE a medication that can be taken as a discreet oral dose to readily treat HAE attacks on-demand, including at the earliest signs before the attack fully develops. Sebetralstat works by targeting the kallikrein-kinin system (KKS) cascade, selectively inhibiting plasma kallikrein and its uncontrolled activity that drives HAE attacks. The firm is also designing an oral Factor XIIa inhibitor for HAE prophylaxis, positioning KalVista to address the full spectrum of HAE disease management. Factor XIIa inhibitor program is developed to address other therapeutic areas, including inflammation and thrombosis.
What is the stock price of KALVISTA PHARMACEUTICALS INC today?
The current stock price of KALV is 15.17 USD. The price decreased by -3.93% in the last trading session.
Does KALVISTA PHARMACEUTICALS INC pay dividends?
KALV does not pay a dividend.
How is the ChartMill rating for KALVISTA PHARMACEUTICALS INC?
KALV has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the market cap for KALVISTA PHARMACEUTICALS INC?
KALVISTA PHARMACEUTICALS INC (KALV) has a market capitalization of 766.84M USD. This makes KALV a Small Cap stock.
KALV Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to KALV. When comparing the yearly performance of all stocks, KALV is one of the better performing stocks in the market, outperforming 93.3% of all stocks.
KALV Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to KALV. KALV has a bad profitability rating. Also its financial health evaluation is rather negative.
KALV Financial Highlights
Over the last trailing twelve months KALV reported a non-GAAP Earnings per Share(EPS) of -3.81. The EPS decreased by -4.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -37.26% | ||
| ROE | -745.01% | ||
| Debt/Equity | 15.81 |
KALV Forecast & Estimates
15 analysts have analysed KALV and the average price target is 31.62 USD. This implies a price increase of 108.44% is expected in the next year compared to the current price of 15.17.